Human gene engineering antibody with Bt Cry1C toxin simulating structure and insecticidal function and mutant of human gene engineering antibody

Through the in vitro enrichment screening of human genetically engineered antibody library and the theoretical design of the antibody "immune network theory", antibodies and mutants that simulate the structure and insecticidal function of Bt Cry1C toxin were obtained, and the resistance and food safety of Bt toxins were solved. The problem is that efficient insecticidal and highly sensitive detection is achieved, ensuring the safety of the environment and food.

CN118930646AActive Publication Date: 2024-11-12JIANGSU ACAD OF AGRI SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411182418.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-12
Estimated Expiration
2044-08-27

AI Technical Summary

Technical Problem

The existing Bt Cry toxin products have caused drug resistance and non-target biological interaction toxicity problems after long-term use, and the food safety of genetically modified crops has attracted attention. Traditional antibody preparation technology is complex and it is difficult to obtain single-chain antibodies with high stability.

Method used

Using the in vitro enrichment screening strategy of antibody library, human genetically engineered antibodies and mutants with simulated Bt Cry1C toxin structure and insecticidal function were obtained, with only heavy chain structure. Through the theoretical design of the antibody "immune network theory" to simulate Bt, we achieved simulated Bt Cry1C toxin structure and insecticidal function replace existing biological insect-resistant materials and conduct high sensitivity detection through IC-ELISA detection method.

Benefits of technology

It realizes efficient insecticidal activity against target pests, reduces the safety risk of Bt toxin use, provides new insect-resistant gene resources, simplifies the antibody preparation process, improves detection sensitivity, and ensures the safety of food and environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930646A_ABST
    Figure CN118930646A_ABST
Patent Text Reader

Abstract

The invention provides a human gene engineering antibody with targeted simulation of a Bt Cry1C toxin structure and an insecticidal function and a high-activity mutant thereof, the nucleotide sequence and the amino acid sequence of the human gene engineering antibody are respectively shown as SEQ IN NO.1 and SEQ IN NO.2, and the nucleotide sequence and the amino acid sequence of the mutant are respectively shown as SEQ IN NO.3 and SEQ IN NO.4; after the antibody and the mutant are subjected to prokaryotic expression, the LD50 of the corresponding protein to plutella xylostella larvae respectively reaches 38.9% and 46.8% of the original Bt Cry1C toxin, and the LD50 of the corresponding protein to cotton bollworm larvae respectively reaches 32.9% and 37.4% of the original Bt Cry1C toxin; the two can also be respectively used as coating antigens in an IC-ELISA detection method to carry out high-sensitivity detection on the Bt Cry1C toxin; the antibody and the mutant thereof can be used as an antigen analogue material for replacing a Bt Cry1C toxin structure, not only can be used as a novel protein insect-resistant material to have potential application value in green prevention and control of agricultural pests, but also can be used for detecting Bt Cry1C toxin residues in environment and food samples, and have broad-spectrum application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel biosafety pesticide and the technical field of pesticide immunological detection, and in particular to a humanized genetically engineered antibody having a structure simulating the Bt Cry1C toxin and insecticidal function, and a mutant thereof and application thereof. Background Art

[0002] Bt Cry toxins are biological macromolecular proteins with highly specific targeted anti-insect function produced by the metabolism of Bacillus thuringiensis (Bt). Their insecticidal spectrum covers a variety of common agricultural and forestry pests and hygienic vectors such as Lepidoptera, Coleoptera, Diptera, Hemiptera, Hymenoptera, as well as nematodes and snails (Palma et al., "Bacillus thuringiensis toxins: an overview of their biocidal activity", Toxins, 2014, Issue 6). Although Bt Cry toxins are numerous and have a wide spectrum of insecticides, the mechanism of action of most of their subtypes on target pests is basically locked in a series of cascade interactions with specific membrane protein receptors such as cadherin, aminopeptidase, alkaline phosphatase, ABC transporter, GTP-coupled regulatory protein on the corresponding insect midgut brush border membrane vesicles (BBMV), thereby causing intestinal digestion and absorption disorders in the insect body, and ultimately causing the growth and development of the insect body to be blocked and even die (Xu Chongxin et al., "Rational Design and Innovative Application Strategy of Insecticidal Proteins Based on Bt Toxins", Chinese Agricultural Science, 2024, No. 1). At present, Bt Cry toxins are widely used in green pest control in the form of microbial expression preparations and transgenic insect-resistant crops, and its commercialized transgenic crops involve important crop types such as rice, corn, soybeans, potatoes, cotton, and tobacco, with an annual global planting area of ​​nearly 200 million hectares, which has led to huge economic value and social and ecological benefits. However, since the commercialization of Bt toxin preparations and transgenic insect-resistant crops in the 1930s and 1990s, respectively, Bt Cry toxin products have been continuously promoted and applied around the world for nearly a hundred years. Potential risks such as target pest resistance induced by their long-term accumulation and cross-toxicity to non-target organisms have become increasingly prominent. In particular, in recent years, the safety of transgenic crop foods has attracted much attention (Koch et al., "The food and environmental safety of Bt crops", Frontiers in Plant Science, 2015, Issue 6).

[0003] In 1974, Danish immunologist Niels K. Jerne first proposed and elaborated on the "immune network theory" of antibodies ("Towards a network theory of the immune system", Ann Immunol, 1974, No. 125), arguing that the entire process in which antigens (Antigen, Ag) enter the animal body to stimulate the immune system to produce antibodies (Antibody, Ab) and induce a series of immune effects until the end is a reversible cascade immune response, in which the idiotypic antigen receptor site on the primary antibody (Ab1) molecule that responds to the antigen can reversely stimulate the immune system to produce a secondary anti-antibody (Ab2) that specifically responds to the idiotypic site of the antibody, namely, anti-idiotypic antibody (Anti-idiotypic antibody, Anti-Id). According to the region and function of the idiotypic antigen receptor site of the target antibody, anti-idiotypic antibodies can be further divided into four major subtypes, namely Ab2α, Ab2β, Ab2γ and Ab2ε, which correspond to the anti-idiotypic antibody types induced by the reverse stimulation of the immune system by the idiotypic antigen receptor framework region, complementary determining region, near complementary determining region and far from complementary determining region on the antibody molecule. Among them, the Ab2β type of anti-idiotypic antibodies are induced by the immune system directly stimulated by the complementary determining region of the idiotypic antigen receptor on the antibody molecule (i.e., the key core region of the antibody idiotype binding to the antigen), and have the antigen "internal image" effect. Its three-dimensional conformation is similar to that of the antigen (Ameri et al., "Idiotypes and anti-idiotypic antibodies: a review", Comparative Clinical Pathology, 2006, No. 4). Therefore, the Ab2β type of anti-idiotypic antibodies have the function of simulating and replacing all or part of the key structure and even biological activity of the antigen.Based on the technical path for preparing anti-idiotypic antibodies in the theory of "immune network theory" of antibodies, Hanoux et al. ("Polyclonal anti-idiotypic antibodies which mimic an epitope of the human prion protein", Molecular immunology, 2009, Issue 6) used animal immunization to create Ab2β anti-idiotypic antibodies that mimic the key receptor structure of human prion protein and can replace it for the treatment of corresponding diseases; Shi et al. ("Preparation monoclonal β-type anti-idiotype antibody of zearalenone and development of green ELISA quantitative detecting technique", Preparative Biochemistry & Biotechnology, 2020, Issue 4) used immunized animals to obtain Ab2β anti-idiotypic monoclonal antibodies that mimic the key characteristic structure of zearalenone, which can replace the original toxin standard for establishing an immunological detection method for screening and analysis of the toxin.

[0004] However, these traditional technologies all use in vivo animal immunization combined with in vitro identification and screening to obtain anti-unique antibodies. The technical process is complicated and it is difficult to obtain the target material, which is not conducive to the subsequent expression preparation and further functional modification. At the same time, the currently common single-chain antibodies (genetically engineered antibodies containing heavy and light chain structures) have the problem of structural instability. Summary of the invention

[0005] In response to the above problems, the present application adopts an in vitro enrichment screening strategy for antibody libraries to screen and obtain human Bt Cry1C toxin anti-idiotypic genetically engineered antibodies (and the corresponding antibody genes can be obtained at the same time). It only has a heavy chain structure and has the advantages of stable nano-antibody structure, strong shuttling ability, and easy expression; the present application also obtains mutants based on the antibody to simulate the structure and insecticidal function of BtCry1C toxin and replace existing biological insect-resistant materials. Specifically, the present invention is implemented as follows:

[0006] First, the present application provides a humanized genetically engineered antibody that has the structure and insecticidal function of simulating Bt Cry1C toxin, whose nucleotide sequence and amino acid sequence are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively. The applicant named the antibody 3A7 anti-I-GEAb.

[0007] Secondly, the present application provides a mutant of the above-mentioned antibody 3A7 anti-I-GEAb, whose nucleotide sequence and amino acid sequence are shown in SEQ IN NO.3 and SEQ IN NO.4, respectively. The applicant named the mutant 3A7 anti-I-GEAb mutant 8.

[0008] Third, the present application also provides the use of humanized genetically engineered antibodies and mutants thereof having amino acid sequences as shown in SEQ ID NO.2 and SEQ ID NO.4 for controlling target pests, such as larvae of diamondback moth and larvae of cotton bollworm.

[0009] Fourth, the present application also provides humanized genetically engineered antibodies and mutants thereof with amino acid sequences as shown in SEQ ID NO.2 and SEQ ID NO.3 to replace Bt Cry1C toxin as coating antigens, and 7C9-mAb F(ab)2 is used as a detection antibody to collaborate with Bt Cry1C toxin antibodies to establish an IC-ELISA detection (indirect competitive enzyme-linked immunosorbent assay) method for specific and highly sensitive detection of Bt Cry1C toxin.

[0010] Fifth, the present application provides a recombinant expression vector, a transgenic cell line or a recombinant engineered bacterium containing the nucleotide sequences of SEQ ID NO.1 and SEQ ID NO.2.

[0011] The present application draws on the theory of antibody "immune network theory" ("Towards a network theory of the immune system", Ann Immunol, 1974, No. 125), in which the Ab2β type anti-idiotypic antibody has the "internal image" effect of the antigen (Ameri et al., "Idiotypes and anti-idiotypic antibodies: a review", Comparative Clinical Pathology, 2006, No. 4), and thus has the functional characteristics of simulating and replacing all or part of the key structure and even the biological activity of the antigen. For the first time, the Bt Cry1C toxin idiotypic monoclonal antibody antigen-binding fragment (7C9-mAb F(ab)2) is specifically designed as the coated target antigen, and an Ab2β anti-idiotypic human genetically engineered antibody (3A7 anti-I-GEAb) with a structure simulating Bt Cry1C toxin and insecticidal function is obtained from a public human gene library, and a mutant with higher activity (3A7 anti-I-GEAb) is obtained by targeting the CDR3 region based on saturation mutation and further screening. The humanized genetically engineered antibody and its mutants were expressed in a prokaryotic system, and the corresponding antibody proteins had lethal activity against the target pests, the diamondback moth larvae and the cotton bollworm larvae; in addition, they were used as coating antigens to replace the Bt Cry1C toxin standard, and in collaboration with the Bt Cry1C toxin antibody, an IC-ELISA detection method was established for the specific and highly sensitive detection of Bt Cry1C toxin.

[0012] The Ab2β anti-idiotypic humanized genetically engineered antibody (3A7 anti-I-GEAb) and its mutant (3A7 anti-I-GEAbmutant 8) obtained by the in vitro targeted screening method have a short preparation cycle and a small amino acid sequence, and are suitable for large-scale in vitro production. At the same time, as a brand-new insect-resistant gene resource, the present invention has important scientific and practical significance for exploring and expanding new insect-resistant gene resources with insecticidal activity simulating Bt toxins, reducing various safety risks existing in the widespread use of existing Bt toxins, and even possibly replacing Bt toxins for biological control of agricultural pests in the future. In addition, the present invention can also be used as a structural substitute for Bt Cry1C toxin standard products, and cooperate with corresponding antibodies to establish an immunoassay method for monitoring Bt Cry1C toxin residues, which can reduce the potential secondary risks brought about by the production and use of Bt Cry1C toxin standard products, achieve the purpose of green detection of Bt Cry1C toxin, and has important significance and broad application prospects for environmental and food safety.

[0013] Compared with the prior art, this application has the following beneficial effects:

[0014] 1. The humanized genetically engineered antibodies (3A7anti-I-GEAb) and their mutants (3A7 anti-I-GEAb mutant 8) created in the present application, which have the structure and insecticidal function of simulating Bt Cry1C toxin, have insecticidal activity against the target pests, namely, Plutella xylostella larvae and Helicoverpa armigera larvae. Moreover, due to the humanized nature of these anti-insect genetically engineered antibodies, they theoretically will not cause obvious heterologous rejection reactions to the human immune system. Therefore, compared with the original Bt Cry toxin, they have greater safety advantages and have important scientific research significance and potential application value.

[0015] 2. The humanized genetically engineered antibody (3A7anti-I-GEAb) and its mutant (3A7 anti-I-GEAb mutant 8) of the present application that has the structure and insecticidal function of simulating Bt Cry1C toxin can be used as coating antigens to replace BtCry1C toxin standards, and cooperate with Bt Cry1C toxin antibodies to establish an IC-ELISA detection method to achieve specific and highly sensitive green detection of Bt Cry1C toxin.

[0016] 3. The amino acid sequences and encoding genes of the humanized genetically engineered antibodies (3A7anti-I-GEAb) and their mutants (3A7 anti-I-GEAb mutant 8) of the present application that have simulated the structure of Bt Cry1C toxin and insecticidal function have been determined, so that these genetically engineered antibody materials can be prepared by soluble expression through a variety of expression systems; in addition, relying on the amino acid and gene information of these genetically engineered antibodies, these materials can also be further functionally modified (such as antigen binding activity, stability) with the help of existing antibody affinity maturation technology, so these genetically engineered materials have great advantages in further preparation or improved application in the later stage. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is a diagram showing the effect of SDS-PAGE analysis of Px-BBMV and Ha-BBMV protein extraction in Example 1;

[0018] Among them, (a) is the effect diagram of Px-BBMV after SDS-PAGE electrophoresis, lane M is the protein standard, and lanes 1-3 are the collected Px-BBMV protein solutions; (b) is the effect diagram of Ha-BBMV after SDS-PAGE electrophoresis, lane M is the protein standard, and lanes 1-2 are the collected Ha-BBMV protein solutions.

[0019] Figure 2The preparation and identification results of the Bt Cry1C toxin idiotypic monoclonal antibody and its antigen-binding fragment in Example 2;

[0020] Among them, (a) is a diagram of the immune effect of Bt Cry toxin; (b) is an IC-ELISAs standard curve using Bt Cry 1C toxin, Px-BBMV and Ha-BBMV as competitive inhibitors to inhibit the binding of the culture supernatant of a fusion cell line named 7C9-mAb to the coated Bt Cry toxin; (C) is an electrophoresis diagram of the antibody protein and its antigen-binding fragment (7C9-mAb F(ab)2) purified after preparing ascites with the 7C9-mAb fusion cell line; (d) is the ELISA binding activity test result of 7C9-mAb and its antigen-binding fragment with Bt Cry1C toxin.

[0021] Figure 3 These are the results of screening and identification of the anti-idiotypic genetically engineered antibody against Bt Cry1C toxin Ab2β in Example 3.

[0022] Figure 4 The results of construction and analysis of the 3A7 anti-I-GEAb mutation library in Example 4.

[0023] Figure 5 These are the results of screening and identification of highly active mutants of 3A7 anti-I-GEAb in Example 4.

[0024] Figure 6 These are the prokaryotic expression and purification results of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 in Example 5.

[0025] Figure 7 These are the anti-insect activity test results of the antibody 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 in Example 6.

[0026] Figure 8 This is the standard curve of IC-ELISAs for Bt Cry1C toxin detection established in Example 7. DETAILED DESCRIPTION

[0027] The reagent formula involved in the embodiment:

[0028] (1) PBS solution

[0029] Weigh 8 g NaCl, 0.2 g KCl, 2.9 g Na2HPO4·12H2O, and 0.2 g KH2PO4, add them into distilled water respectively, and after fully dissolving, make up to 1 L.

[0030] (2) PBST solution

[0031] Add 0.05% Tween-20 by volume to the PBS solution.

[0032] (3) MET buffer

[0033] Weigh 300 mM mannitol, 5 mM EGTA, and 17 mM Tris, add them into distilled water respectively, adjust the pH to 7.5 after fully dissolving, and then make the volume to 1 L.

[0034] (4) Tetramethylbenzidine (TMB) solution:

[0035] Weigh 10 mg of tetramethylbenzidine and dissolve it in 1 ml of dimethyl sulfoxide. Protect from light and store at 4°C for later use.

[0036] (5) Substrate color development solution:

[0037] 10ml formula ingredients: 9.875mL CPBS, 100μL TMB solution, 25μL 20% H2O2 by volume.

[0038] (6) 2×TY liquid medium:

[0039] Add 16 g of tryptone, 10 g of yeast extract and 5 g of NaCl to 900 mL of double distilled water, stir to mix, make up to 1 L with double distilled water, place in an autoclave, sterilize at 121°C for 20 min, cool, and store at 4°C for later use.

[0040] (7) 2×TY-AG liquid culture medium:

[0041] Ampicillin with a final concentration of 100 μg / ml and glucose with a mass ratio of 1% were added to the 2×TY culture medium.

[0042] (8) 2×TY-AK liquid culture medium:

[0043] Ampicillin and kanamycin were added to the 2×TY medium at a final concentration of 100 μg / ml.

[0044] (9) 2×TY-AKG liquid culture medium:

[0045] Ampicillin at a final concentration of 100 μg / ml, kanamycin at a mass ratio of 50 μg / ml and glucose at a mass ratio of 1% were added to the 2×TY culture medium.

[0046] (10) TYE solid medium:

[0047] Add 15.0 g agarose, 8 g NaCl, 10 g tryptone, and 5 g yeast extract to 900 ml double distilled water, dilute to 1 L with double distilled water, place in an autoclave, sterilize at 121°C for 20 min, cool, and store at 4°C for later use. (11) TYE-AG solid culture medium:

[0048] Ampicillin with a final concentration of 100 μg / ml and glucose with a mass ratio of 1% were added to TYE solid culture medium.

[0049] (12) PEG / NaCl solution:

[0050] Weigh 20 g PEG 8000 and 14.61 g NaCl, add 80 ml deionized water, make up to 100 ml, place in an autoclave, sterilize at 121°C for 20 min, cool, and store at 4°C for later use.

[0051] Sources of materials involved in the examples:

[0052] Bt Cry1C toxin standard was purchased from Meiyan (Beijing) Agricultural Technology Co., Ltd.;

[0053] The Balb / c model experimental mice were provided by the Comparative Medicine Center of Yangzhou University.

[0054] Goat anti-mouse IgG-HRP, anti-M13 mAb-HRP, and anti-His mAb-HRP were purchased from Beijing Qingke Biotechnology Co., Ltd.

[0055] Freund's complete adjuvant, Freund's incomplete adjuvant, hypoxanthine thymidine (HT), hypoxanthine aminopterin thymidine (HAT), and polyethylene glycol (PEG) were all purchased from Sigma.

[0056] DMEM high-glucose culture medium was purchased from Nanjing Youqing Biotechnology Co., Ltd.

[0057] Fetal bovine serum was purchased from Nanjing Novazon Biotechnology Co., Ltd.

[0058] TMB substrate colorimetric solution was purchased from Beijing Pulilai Gene Technology Co., Ltd.

[0059] Cell culture plates (9-, 24-, and 96-well), cell culture flasks, and ELISA plates were purchased from Corning;

[0060] Human genetic engineering antibodies other than "Ab2β", second-instar larvae of diamondback moth, and second-instar larvae of cotton bollworm were all provided by the Key Laboratory of Agricultural Product Quality Safety Control Technology and Standards of the Ministry of Agriculture, Jiangsu Academy of Agricultural Sciences;

[0061] Phage display human genetic engineering antibody library (human heavy chain single domain antibody library), E. coli TG1 bacteria and helper phage KM13 were purchased from Source BioScience, UK;

[0062] pET26b plasmid vector, E. coli BL21, 2×PCR Mix-buffer, Not I / Nco I endonuclease, DNA maker, and protein maker were purchased from New England Biolabs.

[0063] The other reagents used were of analytical grade.

[0064] The nucleotide sequences and amino acid sequences involved in the examples are:

[0065] SEQ ID NO.1:

[0066] ATGGCCCAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCCTGTGCAGCCT

[0067] CCGGA GATATGATTAGCGATAAGGCTATGGCC TGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCA GCGAT

[0068] TAAGACACCAGGAGGTAGCACA TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAAC

[0069] ACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCG AGTTCGTA TGCGATTAGGTCGGAGTCTGTTAAGGACGCGGACTTGGCGTTT TGGGGTCAGGGAACCCTGGTCACCGTCTCGAGCGCGGCCGCA;

[0070] SEQ ID NO.2:

[0071] MAQVQLLESGGGLVQPGGSLRLSCAASG DMISDKAMAWVRQAPGKGLEWVS AIKTPGGST YYADSVKGRFTISRDNSKN TLYLQMNSLRAEDTAVYYCASS YAIRSESVKDADLAF WGQGTLVTVSSAAA.

[0072] SEQ ID NO.3:

[0073] ATGGCCCAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGTCCCTGCGTCTCTCCTGTGCAGCCT

[0074] CCGGA GATATGATTAGCGATAAGGCTATGGCC TGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCA GCGAT

[0075] TAAGACACCAGGAGGTAGCACA TACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAAC

[0076] ACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGAGTTCG TA TGCGATTAGGTCGGAGTCTCCGAAGTTCGCGCCTTTGGCGTTT TGGGGTCAGGGAACCCTGGTCACCGTCTCGAGCGCGGCCGCA.

[0077] SEQ ID NO.4:

[0078] MAQVQLLESGGGLVQPGGSLRLSCAASG DMISDKAMA WVRQAPGKGLEWVS AIKTPGGST YYADSVKGRFTISRDNSKN TLYLQMNSLRAEDTAVYYCASS YAIRSESPKFAPLAF WGQGTLVTVSSAAA.

[0079] SEQ IN NO.5:CAGGAAACAGCTATG.

[0080] SEQ IN NO.6:CTATGCGGCCCCATT;

[0081] SEQ IN NO.7:ATGGCCCAGGTGCAGCTGTTGGAGTCT;

[0082] SEQ IN NO.8: TGCGGCCGCGCTCGAGACGGTGAC;

[0083] SEQ IN NO.9:

[0084] CGCGGCCGCTGCGGCCGCGCTCGAGACGGTGACCAGGGTTCCCTGACCCCANNKNNKNNKNNKNNKNNKNNKNNKNNKN NKNNKNNKNNKNNKCGAACTCGC;

[0085] SEQ IN NO.10: CCATGGGTCATGGCCCAGGTGCAGCTGTTGGAGTCT;

[0086] SEQ IN NO.11: CGCGGCCGCTGCGGCCGCGCTCGAGACGGTGAC;

[0087] SEQ IN NO.12: TAATACGACTCACTATAGGGG;

[0088] SEQ IN NO.13: GCTAGTTATTGCTCAGCG.

[0089] Example 1 Preparation of Plutella xylostella BBMV (Px-BBMV) and Helicoverpa armigera BBMV (Ha-BBMV) proteins

[0090] Referring to the method reported by Xie et al. (“Docking-based generation of antibodies mimicking Cry1A / 1Bprotein binding sites as potential insecticidal agents against diamondbackmoth(Plutella xylostella)”, Pest Management Science, 2021, Issue 10), 4th-instar larvae of Plutella xylostella (1000) and larvae of cotton bollworm (80) were taken, the midguts were extracted respectively, washed in a precooled 0.15 M sodium chloride solution, removed and filtered; then placed in 10 ml of Homogenize in a glass homogenizer containing MET buffer for 1 min, ice bath for 1 min, and repeat 10 times; aspirate the corresponding homogenate and place it in a 50 ml centrifuge tube, add equal volumes of 24 mM MgCl2 solution, vortex mix, and ice bath for 15 min; then centrifuge at 3000 g for 15 min, take the supernatant, and then centrifuge at 15000 g for 50 min, discard the supernatant, and resuspend the precipitate (i.e., Px-BBMV and Ha-BBMV proteins, respectively) in HEPES solution with a mass concentration of 1 mM for storage.

[0091] The electrophoretic patterns of Px-BBMV and Ha-BBMV protein extraction obtained in this example are shown in Figures 1 and 2. Figure 1 (a) and Figure 1 As shown in (b), the total protein concentration in the Px-BBMV solution was 5.76 mg / ml, and the total protein concentration in the Ha-BBMV solution was 2.19 mg / ml.

[0092] Example 2 Preparation and identification of antigen-binding fragments of monoclonal antibodies to the idiotypic Bt Cry1C toxin

[0093] Preparation process of Bt Cry1C toxin monoclonal antibody: 800 μg of Bt Cry1C toxin standard was dissolved in 100 μL PBS solution and fully mixed with 100 μL complete Freund's adjuvant for emulsification, and then injected into the peritoneal cavity of 6-week-old healthy female Balb / c mice by intraperitoneal injection; two weeks later, 100 μg of Bt Cry1C toxin standard was dissolved in 100 μL PBS solution and fully mixed with 100 μL incomplete Freund's adjuvant for emulsification, and also injected into the peritoneal cavity of the test mice; two weeks later, 100 μg of Bt Cry1C toxin standard was dissolved in 100 μL PBS solution and fully mixed with 100 μL incomplete Freund's adjuvant for emulsification, and also injected into the peritoneal cavity of the test mice; one week later, 125 μg of Bt The Cry1C toxin standard was dissolved in 100 μL PBS solution and directly injected into the abdominal cavity of the test mice; after another week, the spleen B cells of the test mice were collected for the preparation of monoclonal antibody fusion cell lines. Before each round of immunization, a small amount of blood was collected by tail cutting to extract serum for indirect noncompetitor ELISA (INC-ELISA) to determine and analyze the corresponding immune effects; the specific steps were carried out according to the method reported by Jin et al. ("Rational design and application of broad-spectrumantibodies for Bt Cry toxins determination", Analytical Biochemistry, 2024, No. 693). After four rounds of immunization, the immune effect of Bt Cry toxin was as follows: Figure 2 As shown in (a), it can be seen that OD 450 >1.0 was used as the standard, and the calibration of the test mouse serum reached 1:100000, indicating a good immune effect.

[0094] Cell fusion process: After the immune effect is determined to reach an acceptable level, the mouse is dislocated by cervical dislocation, and then soaked in 75% alcohol for 10 minutes, then taken out and drained. In a sterile environment, the spleen is removed and ground in an incomplete culture medium (HAT culture medium). After filtering, the grinding liquid is collected and divided into 20 mL / tube, and the spleen cells are counted under a microscope. Splenocytes and SP2 / 0 myeloma cells are mixed at a cell number of 5:1 under equal volume conditions, and then centrifuged at 1000 rpm for 10 minutes in a 37°C centrifuge. The supernatant is discarded, and the precipitated mixed cells are resuspended with 1 mL PEG at 40°C and allowed to stand for 1 minute, followed by adding 15 mL HAT culture medium, standing in a 37°C incubator for 10 minutes, and then centrifuged at 800 rpm for 8 minutes. The precipitated cells are first resuspended with 5 mL HAT culture medium, and then HAT culture medium is added to make the volume 50 mL, and finally divided into 96-well plates at 100 μL / well and placed in a 37°C incubator for culture. Five days later, fresh HAT medium was added to the cells at 100 μL / well. Two days later, half of the culture medium in the wells was aspirated and an equal volume of fresh HAT medium was added. The cells were then cultured until the cells occupied about 1 / 10 of the bottom of the well. The cell culture medium was used for INC-ELISA to analyze the binding activity of the immunogen Bt Cry1C toxin.

[0095] Identification process of target Bt Cry1C toxin idiotypic monoclonal antibody: Referring to the indirect competitive enzyme-linked immunosorbent assay (IC-ELISA) established by Xu et al. (“Screening and identification of vancomycin anti-idiotypic antibodies for against Staphylococcus aureus from a human phage display domain antibody library”, Immunology Letters, 2022, Issue 246), BtCry 1C toxin, Px-BBMV and Ha-BBMV were used as competitive inhibitors, respectively. By analyzing their inhibition of the binding activity of the supernatant of fusion cells and the coated Bt Cry 1C toxin, the target Bt Cry1C toxin idiotypic monoclonal antibody was identified. The specific method is as follows: Bt Cry1C toxin was diluted to a mass concentration of 2 μg / mL with PBS buffer, and 100 μL was added to each well of a 96-well ELISA plate, and coated overnight at 4°C. Remove the coated plate, wash the plate with 300 μL / well PBST buffer, add MPBS solution at 300 μL / well, and incubate at 37°C for 2 hours. Remove the blocked plate, wash the plate with 300 μL / well PBST buffer, add 50 μL of fusion cell culture supernatant and 50 μL of competitive inhibitor (Bt Cry 1C toxin, Px-BBMV, Ha-BBMV) solution diluted with PBS solution in a series of concentration gradients (0.1, 0.5, 1.5, 10, 20, 50, 100 and 1000 ng / mL) to each well, and the negative control is PBS, incubate at 37°C for 1 hour. Remove the incubation plate, wash the plate with 300 μL / well PBST buffer, add Goat anti-mouse IgG-HRP (diluted 1:5000 in PBS buffer) secondary antibody at 100 μL / well, and incubate at 37°C for 1 hour. After washing the plate with 300 μL / well PBST buffer, add TMB colorimetric solution at 100 μL / well, develop the color for 15 minutes at 37°C in the dark, and measure the OD of the relevant reaction wells. 450 The corresponding IC-ELISAs competitive inhibition rate standard curve was drawn according to the calculation formula [(PSN)] / (PN)]×100%; where P represents the OD of the positive control 450 Value (test sample is 50 μL of fusion cell culture supernatant + 50 μL PBS solution), S represents the OD of each standard 450Value (test sample is 50 μL of fusion cell culture supernatant and 50 μL of competitive inhibitor solution with a series of concentration gradients diluted with PBS solution), N represents the OD of the negative control 450 Value (test sample is 50μL PBS solution). Among them, the fusion cells that can inhibit the binding of the test supernatant with the coated Bt Cry 1C toxin by using Bt Cry 1C toxin, Px-BBMV and Ha-BBMV as competitive inhibitors are determined to be Bt Cry1C toxin idiotype monoclonal antibodies; the corresponding fusion cell lines can be used to prepare the target Bt Cry1C toxin idiotype monoclonal antibodies and their antigen-binding fragments, and the method is as follows: the number of cells of the corresponding subclone fusion cell lines identified as the target Bt Cry1C toxin idiotype monoclonal antibodies is quantified to 10 in DMEM high-glucose medium. 6 , and then injected into the abdominal cavity of female mice at a rate of 0.5 ml / mouse. After 5 days of feeding, ascites was extracted from the abdominal cavity of the test mice. Finally, referring to the saturated ammonium sulfate precipitation method reported by our team earlier ("Preparation of polyclonal antibodies against Bt (Cry1F) toxin and its detection application", Xu Chongxin et al., Quality and Safety of Agricultural Products, Issue 4, 2016) and HiTrap Protein G HP (refer to the product operation manual for steps) column purification method, the target Bt Cry1C toxin idiotypic monoclonal antibody (named 7C9-mAb) was separated and purified from the extracted ascites, and its antigen binding fragment (named 7C9-mAb F(ab)2) was purified by Pierce purification method of Thermo Scientific (USA). TM The F(ab)2Preparation Kit product manual was used to prepare the sample, and its antigen binding activity was analyzed by INC-ELISA.

[0096] Figure 2 (b) shows the IC-ELISAs standard curves using Bt Cry 1C toxin, Px-BBMV and Ha-BBMV as competitive inhibitors to inhibit the binding of the culture supernatant of the fusion cell line named 7C9-mAb to the coated Bt Cry toxin. The corresponding inhibitory concentrations were measured to be 7.7, 19.4 and 26.2 ng / ml, respectively, indicating that the inhibitory activity was relatively strong, thereby indicating that the monoclonal antibody meets the characteristics of the Bt Cry1C toxin unique monoclonal antibody.

[0097] Figure 2(c) shows the antibody protein and its antigen-binding fragment (7C9-mAb F(ab)2) obtained by preparing ascites with 7C9-mAb fusion cell line, wherein lane M is a protein marker, lane 1 is ascites containing 7C9-mAb, lane 2 is a protein solution of ascites containing 7C9-mAb after crude purification by saturated ammonium sulfate, lane 3 is a protein solution of 7C9-mAb after purification by HiTrap Protein G HP column, lane 4 is a protein solution of 7C9-mAb after protein purified by HiTrap Protein G HP column and denatured by β-mercaptoethanol, lane 5 is a protein solution of 7C9-mAb pure protein after Pierce TM Lane 6 is the protein solution of 7C9-mAb F(ab)2 after being digested and purified by F(ab)2 Preparation Kit, and lane 6 is the protein solution of 7C9-mAb F(ab)2 after being denatured by β-mercaptoethanol. Both are consistent with the molecular weight characteristics of the corresponding proteins, indicating that the preparation of Bt Cry1C toxin idiotypic monoclonal antibody and its antigen-binding fragment was successful and the effect was good.

[0098] Figure 2 (d) shows the ELISA binding activity of 7C9-mAb and its antigen-binding fragment with Bt Cry1C toxin. The results show that both have strong binding activity to Bt Cry1C toxin.

[0099] Example 3 Screening and identification of anti-idiotypic genetically engineered antibodies against Bt Cry1C toxin Ab2β

[0100] (1) Take 20 μl of the phage display human genetic engineering antibody library and add it to 200 ml of 2×TY-AG liquid culture medium. Incubate at 37°C until OD 600 is 0.4, take 50ml of bacterial solution, add 1×10 12 pfu / ml helper phage KM13 was used for superinfection. After incubation at 37°C for 30 min, the cells were centrifuged at 3300 g for 10 min, the supernatant was discarded, and the pellet was resuspended in 100 ml of 2×TY-AKG liquid medium and cultured at 30°C overnight. The next day, the cells were centrifuged at 3300 g for 30 min, the supernatant was collected and added with 20 ml of PEG / NaCl solution, and the pellet was resuspended in 4 ml of PBS after an ice bath for 1 h. The resuspended pellet was centrifuged at 11600 g for 10 min, and the supernatant was the amplified phage antibody library, which was titrated to 1×10 with PBS solution. 9 pfu / ml for standby use;

[0101] (2) The amplified phage antibody library obtained in step 1 was subjected to a total of 6 rounds of enrichment and panning (7C9-mAb F(ab)2) and Px-BBMV were used as coating antigens for 3 rounds of enrichment and panning respectively): In the first round of enrichment and panning, 4 ml of 100 μg / ml BtCry1C toxin idiotypic monoclonal antibody antigen-binding fragment (7C9-mAb F(ab)2)) was coated on the bottom of a cell culture bottle and incubated at 4°C overnight. The next day, the cell culture bottle was washed 3 times with 1 ml of PBS, and then 1 ml of the amplified phage antibody library and 4 ml of 3% MPBS solution were added. The bottle was placed on a shaker and slowly shaken at room temperature for 1 hour. After standing for 1 hour, the liquid in the culture bottle was poured out, and the bottle was washed 20 times with 1 ml of PBST solution, and 1 ml of 10mg / ml trypsin was used to elute the specifically bound phage antibodies. The eluate was the phage antibodies from the first round of panning. The phage antibodies were amplified according to step 1 and fixed to 1×10 9 pfu / ml for standby; in the 2nd, 3rd, 4th, 5th and 6th rounds of enrichment and panning, the coated materials were: 4ml 100μg / ml Px-BBMV, 4ml 50μg / ml 7C9-mAb F(ab)2, 4ml 50μg / ml Px-BBMV, 4ml 50μg / ml 7C9-mAb F(ab)2 and 4ml 25μg / ml Px-BBMV, respectively. The phage genetic engineering antibody library used was the secondary library (titer of 1×10 9 pfu / ml), and the panning method was the same as the first round; 10 μl of phage antibodies screened in the sixth round were used to infect 1 ml of TG1 bacteria in the logarithmic growth phase, incubated at 37°C for 1 hour, and then spread on TYE-AG solid culture medium and cultured at 37°C overnight; the next day, single colonies were randomly picked and inoculated into a 96-well plate containing 100 μl / well 2×TY-AG liquid culture medium, and cultured at 37°C overnight; the next day, 2 μl of bacterial solution was aspirated from the plate well and transferred to a new 96-well plate well, incubated at 37°C for 2 hours, and 25 μl of a titer of 10 12 pfu / ml of helper phage KM13, incubated at 30°C for 2h, centrifuged at 1800g for 10min, resuspended the precipitate in 150μl 2×TY-AK liquid medium and cultured at 30°C overnight, centrifuged at 1800g for 30min the next day, and the supernatant was collected respectively;

[0102] (3) 7C9-mAb F(ab)2 and Px-BBMV at a concentration of 2 μg / ml were added to a 96-well plate, 100 μl / well, and incubated at 4°C overnight. The next day, 100 μl of the supernatant obtained in step 2 was added to each well. For the negative control, 100 μl of 2×TY-AK liquid culture medium was added. The plate was incubated at 37°C for 2 h. After washing the plate with 250 μl PBST, 100 μl of 1:3000 diluted HRP-sheep anti-M13-IgG was added to each well and incubated at 37°C for 2 h. 100 μl of substrate color development solution was added to each well and reacted at room temperature for 10 to 20 min until blue appeared. Finally, 50 μl of 2 mol / L H2SO4 was added to each well to quickly terminate the reaction and the OD was measured using an enzyme reader. 450 The OD values ​​of the same solution coated with 7C9-mAb F(ab)2 and Px-BBMV were 450 Value / negative control OD 450 If the values ​​are all greater than 3.0, they are preliminarily judged to be positive, and the supernatant in step 2 corresponding to the solution is the screened supernatant preliminarily judged to contain the Bt Cry1C toxin Ab2β anti-idiotypic genetically engineered antibody.

[0103] (4) Referring to the IC-ELISA method steps established in the “Target Bt Cry1C toxin idiotypic monoclonal antibody identification process”, 100 μl / well PBS solution was diluted to a mass concentration of 2 μg / ml 7C9-mAb F(ab)2 as the coating antigen, and 7C9-mAb F(ab)2, Px-BBMV and Ha-BBMV were used as competitive inhibitors to inhibit the binding activity of the supernatant of the Bt Cry1C toxin Ab2β anti-idiotypic genetically engineered antibody preliminarily identified in (3) with the coating antigen 7C9-mAb F(ab)2. The step of adding the “Goat anti-mouse IgG-HRP (diluted 1:5000 in PBS buffer) secondary antibody” was replaced by the “anti-M13mAb-HRP (diluted 1:3000 in PBS buffer) secondary antibody”, and the other steps remained unchanged. The standard curve of the corresponding IC-ELISA competitive inhibition rate was drawn according to the calculation formula [(PSN)] / (PN)]×100%; where P represents the OD of the positive control 450 Value (test sample is 50 μL of supernatant preliminarily identified as Bt Cry1C toxin Ab2β anti-idiotypic genetic engineering antibody + 50 μL PBS solution), S represents the OD of each standard 450 Value (the test sample is 50 μL of the supernatant of the anti-idiotypic genetic engineering antibody preliminarily identified as Bt Cry1C toxin Ab2β and 50 μL of a series of concentration gradient competitive inhibitor solutions diluted with PBS solution), N represents the OD of the negative control 450Value (test sample is 50 μL PBS solution).

[0104] Using 7C9-mAb F(ab)2, Px-BBMV and Ha-BBMV as competitive inhibitors, the corresponding genetically engineered antibody that can simultaneously inhibit the binding of the supernatant of the Bt Cry1C toxin Ab2β anti-idiotypic genetically engineered antibody preliminarily identified in (3) to the coated antigen 7C9-mAb F(ab)2 can be confirmed as the "Bt Cry1C toxin Ab2β anti-idiotypic genetically engineered antibody". The corresponding antibody gene was sent to General Biotechnology Co., Ltd. (Anhui) for sequencing (sequencing universal primers, sequencing universal primers, upstream LMB3 nucleotide sequence is shown in SEQ IN NO.5, downstream PHEN nucleotide sequence is shown in SEQ IN NO.6.

[0105] Figure 3 The results of screening and identification of the anti-idiotypic genetically engineered antibody of Bt Cry1C toxin Ab2β in this example. Among them, (a) is the primary library after enrichment and panning of the anti-idiotypic genetically engineered antibody of Bt Cry1C toxin Ab2β displayed by the target phage, and 7C9-mAb F(ab)2 and Px-BBMV were used as coating antigens for 3 rounds of enrichment and panning, and the results of polyclonal phage ELISA analysis showed that their ELISA binding activity to the coated 7C9-mAb F(ab)2 and Px-BBMV gradually increased, indicating that the target genetically engineered antibody displayed by the phage was effectively enriched. (b) The positive clones of the genetically engineered antibody labeled 3A7 (named 3A7 anti-I-GEAb by the applicant) showed strong binding activity to both the coated 7C9-mAb F(ab)2 and Px-BBMV as determined by monoclonal phage ELISA, where Nc-1 was a negative control clone randomly selected during the screening process that had no binding activity to 7C9-mAb F(ab)2 and Px-BBMV. (c) is the IC-ELISAs standard curve using 7C9-mAb F(ab)2, Px-BBMV and Ha-BBMV as competitive inhibitors to inhibit the binding of the corresponding positive monoclonal phage displayed expression supernatant of 3A7 anti-I-GEAb to the coated 7C9-mAb F(ab)2. The corresponding median inhibition concentrations were measured to be 8.82, 10.70 and 13.20 ng / ml, respectively, indicating that the inhibitory activity was relatively strong. This shows that the monoclonal phage displayed genetically engineered antibody meets the characteristics of the Bt Cry1C toxin Ab2β anti-idiotypic genetically engineered antibody.

[0106] The applicant further sequenced the antibody 3A7 anti-I-GEAb obtained in this example, and its amino acid sequence is shown in SEQ IN NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ IN NO.1, wherein the underlined portion is the heavy and light chain CDR region.

[0107] Example 4 Construction of the Anti-idiotypic Genetically Engineered Antibody Mutation Library of Bt Cry1C Toxin Ab2β and Screening and Identification of Highly Active Mutants

[0108] The strategy for constructing the anti-idiotypic genetically engineered antibody mutation library of Bt Cry1C toxin Ab2β was based on the method reported by Zhong et al. (“Broadspecificity immunoassay for detection of Bacillus thuringiensis Cry toxins through engineering of a single chain variable fragment with mutagenesis and screening”, International journal of biological macromolecules, 2018, Issue 107). The positive human phage display genetically engineered antibody strain named 3A7 anti-I-GEAb obtained by screening in Example 3 was cultured in 2×TY-A medium overnight, and the corresponding target genetically engineered antibody gene was prepared by bacterial liquid PCR amplification the next day: 50 μL of PCR reaction system contained 25 μL of 2×PCR Mix-buffer, 1 μL of 3A7anti-I-GEAb corresponding bacterial liquid culture, 1 μL of upstream primer (whose nucleotide sequence is shown in SEQ IN NO.7), 1 μL of downstream primer (whose nucleotide sequence is shown in SEQ IN NO.8) and 22 μL of ddH2O. The PCR reaction conditions were pre-denaturation at 94°C for 5 min, then denaturation at 94°C for 1 min, annealing at 56°C for 1 min, extension at 72°C for 1 min, and so on for 35 cycles, and finally extension at 72°C for 10 min. The PCR product can be used as a gene template for constructing a mutation library after being purified by Sigma's GenElute Kits (see the kit product manual for steps): 50 μL of PCR reaction system contains 25 μL of 2×PCR Mix-buffer, 1 μL of 3A7 anti-I-GEAb gene PCR amplification product, 0.5 μL of upstream primer (CCATGGGTCATGGCCCAGGTGCAGCTGTTGGAGTCT), 0.1 μL of downstream primer targeting random saturation mutation in the CDR3 region of the 3A7anti-I-GEAb gene (the nucleotide sequence of which is shown in SEQ IN NO.9) and 23.4 μL of ddH2O.

[0109] The PCR reaction conditions are: pre-denaturation at 95°C for 10 min, denaturation at 95°C for 1.5 min, annealing at 59°C for 1.5 min, extension at 72°C for 1.5 min, and this cycle for 30 times, and finally extension at 72°C for 15 min. The PCR product can be used to construct a mutation library after purification using Sigma's GenElute Kits (see the kit product manual for steps).

[0110] The corresponding mutant gene of 3A7 anti-I-GEAb was double digested with Not I / Nco I endonucleases and cloned into the pIT2 phagemid vector, and then electroporated into E. coli TG1 competent cells, and then coated on TYE-A plate culture medium and cultured overnight at 37°C. The colonies grown were collected to construct the mutant library targeting the CDR3 region of 3A7 anti-I-GEAb. The detailed operation steps were performed with reference to the literature (Xu et al., "Construction of an immunized rabbit phage display library for selecting high activity against Bacillus thuringiensis Cry1Ftoxin single-chain antibodies", Journal of agricultural and food chemistry, 2017, total issue 651). The screening and identification process of 3A7 anti-I-GEAb high-activity mutants is consistent with Example 3.

[0111] Figure 4 The construction and analysis results of the antibody 3A7 anti-I-GEAb mutation library in this example, wherein: (a) is the electrophoresis diagram of the PCR products of 3A7anti-I-GEAb and its mutants, wherein lane M is a nucleotide marker, lane ck is a control group without adding a gene template, lane 1 is the PCR amplification product of the 3A7 anti-I-GEAb gene, and lanes 2-4 are PCR products targeting mutations in the CDR3 region of the 3A7anti-I-GEAb gene as a template; the results show that the corresponding PCR products are consistent with the size of the target gene of 3A7anti-I-GEAb, indicating that the PCR amplification is successful. (b) is the electrophoresis of the PCR amplification products of random single colonies of the 3A7anti-I-GEAb mutation library constructed in this example: lane M is a nucleotide marker, lane ck is a control group without gene template, and lanes 1-23 are the PCR amplification products of the corresponding 3A7 anti-I-GEAb mutant genes of randomly selected single colonies; the results show that the PCR products of the corresponding mutants are consistent with the size of the target gene of 3A7 anti-I-GEAb, indicating that the mutation library was successfully constructed. (c) is the diversity analysis of the amino acid alignment of the CDR3 region after sequencing of single colonies 1-23 in (b), and the structure shows that the amino acid diversity in this region is good, further confirming that the mutation library was successfully constructed.

[0112] Figure 5The results of screening and identification of highly active mutants of antibody 3A7 anti-I-GEAb in this example. Among them, (a) is the primary library after enrichment and panning of 3A7 anti-I-GEAb mutants displayed by target phage, and 7C9-mAb F(ab)2 and Px-BBMV were used as coating antigens for 2 rounds of enrichment and panning, respectively. The results of polyclonal phage ELISA analysis showed that their ELISA binding activity to coated 7C9-mAb F(ab)2 and Px-BBMV gradually increased, indicating that the target genetically engineered antibodies displayed by phage were effectively enriched. (b) The positive clones of the 3A7 anti-I-GEAb mutant 8 (named by the applicant as 3A7 anti-I-GEAb mutant 8) determined by monoclonal phage ELISA have higher binding activity to both the coated 7C9-mAb F(ab)2 and Px-BBMV than the original 3A7 anti-I-GEAb, and Nc-1 is a negative control clone randomly selected during the screening process that does not have binding activity to 7C9-mAb F(ab)2 and Px-BBMV; the corresponding antibody gene of 3A7 anti-I-GEAb mutant 8 was sent to General Biotech (Anhui) for sequencing. (Universal sequencing primers: LMB3 for upstream and PHEN for downstream).

[0113] The mutant 3A7 anti-I-GEAb mutant 8 was sequenced, and its amino acid sequence is shown in SEQ IN NO.4, and the nucleotide sequence of the encoding gene is shown in SEQ IN NO.3, where the underlined part is the heavy and light chain CDR region. Compared with the original antibody, the mutant has the same amino acids except that the three amino acids in the CDR3 region have mutated. The amino acids in the CDR3 region of the antibody 3A7anti-I-GEAb are "YAIRSESVKDADLAF", while the CDR3 region of the mutant 3A7 anti-I-GEAbmutant 8 is "YAIRSESPKFAPLAF".

[0114] Example 5 Expression and purification of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8

[0115] The corresponding strains of 3A7 anti-I-GEAb obtained in Example 3 and 3A7 anti-I-GEAb mutant 8 obtained in Example 4 were cultured in 2×TY-A medium overnight, and the corresponding target genetic engineering antibody genes were prepared by bacterial liquid PCR amplification the next day: 50 μL of PCR reaction system contained 25 μL of 2×PCR Mix-buffer, 1 μL of 3A7anti-I-GEAb corresponding bacterial liquid culture, 1 μL of upstream primer (SEQ IN NO.10), 1 μL of downstream primer (SEQ IN NO.11) and 22 μL of ddH2O. The PCR reaction conditions were pre-denaturation at 94°C for 5 min, then denaturation at 94°C for 1 min, annealing at 56°C for 1 min, extension at 72°C for 1 min, and so on for 35 cycles, and finally extension at 72°C for 10 min.

[0116] The amplified PCR products were double digested with Not I / Nco I nucleases and cloned into pET26b plasmid vectors, then transformed into E. coli BL21 competent cells, and then spread on LB-K plate culture medium and cultured at 37°C overnight; the next day, single colonies were randomly picked and amplified by PCR and sequenced using T7 universal primers (upstream primer SEQ IN NO.12, downstream primer SEQ INNO.13).

[0117] The positive monoclonal colonies containing the corresponding target genes of 3A7 anti-I-GEAb and 3A7 anti-I-GEAb mutant 8 were identified and transferred to LB-K liquid medium, and cultured in a 37°C shaker at 250 rpm until the logarithmic growth phase (about 2.5 h), and then IPTG inducer was added until its mass concentration reached 0.8 mM, and then the shaker temperature was adjusted to 28°C, and the expression was induced for 12 h. The next day. The culture was removed and placed in a 4°C centrifuge at 6000g for 15 min, the precipitated cells were collected and resuspended in PBS buffer, and then ultrasonically disrupted in an ice bath (ultrasonic conditions: 300W, working 2.5s, rest 2s, and lasting 30min). The ultrasonically disrupted whole cell lysate was taken out and centrifuged at 10,000 g for 30 min in a 4°C centrifuge. The supernatant was taken out and then the corresponding target 3A7 anti-I-GEAb and 3A7 anti-I-GEAb mutant 8 proteins were purified by column purification using His-Trap HP affinity chromatography (see the product manual for steps) produced by GE Company, USA.

[0118] Figure 6The following are the results of prokaryotic expression and purification of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 in this example, wherein (a) is the electrophoresis diagram of the PCR amplification products of the corresponding genes of 3A7 anti-I-GEAb and 3A7 anti-I-GEAb mutant 8: lane M is DNA marker, ck1 is a blank control group without gene template, ck2 is a negative control group with pET26b empty plasmid as template, 1-3 are positive monoclonal clones with bacteria containing pET26b-3A7 anti-I-GEAb recombinant plasmid as template, and 4-6 are positive monoclonal clones with bacteria containing pET26b-3A7 anti-I-GEAb mutant 8 recombinant plasmid as template. (b) is the result of double enzyme digestion of pET26b-3A7 anti-I-GEAb recombinant plasmid, where M is DNA marker, 1 is the control group after double digestion of pET26b empty plasmid with Nco I / Not I nuclease, and 2 is the positive group after double digestion of pET26b-3A7 anti-I-GEAb recombinant plasmid with Nco I / Not I nuclease. (c) is the result of double enzyme digestion of pET26b-3A7 anti-I-GEAb mutant 8 recombinant plasmid, where lane M is DNA marker,

[0119] 1 is the control group after pET26b empty plasmid was double digested with Nco I / Not I endonuclease, 2 is pET26b-3A7

[0120] The positive group after the anti-I-GEAb mutant 8 recombinant plasmid was double digested by Nco I / Not I endonucleases. (d) is the SDS-PAGE analysis result of the induced expression of pET26b-3A7 anti-I-GEAb protein, where lane M is a protein marker and lane 1 is the whole cell lysate after the pET26b-3A7 anti-I-GEAb recombinant plasmid vector was transformed into E.coli BL21 for induced expression and then ultrasonically broken. (e) is the SDS-PAGE analysis result of the induced expression of pET26b-3A7 anti-I-GEAb mutant 8 protein, where lane M is a protein marker and lane 1 is the whole cell lysate after the pET26b-3A7 anti-I-GEAb mutant 8 recombinant plasmid vector was transformed into E.coliBL21 for induced expression and then ultrasonically broken. (f) is the SDS-PAGE analysis result of 3A7 anti-I-GEAb and 3A7 anti-I-GEAb mutant 8 proteins after column purification, wherein lane M is protein marker, lane 1 is the purified 3A7 anti-I-GEAb protein, and lane 2 is the purified 3A7 anti-I-GEAb mutant 8 protein.

[0121] The above test results indicate that the prokaryotic expression recombinant plasmid clones of the corresponding genes of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 were successfully constructed, and after induced expression and column purification, 3A7 anti-I-GEAb protein with a concentration of 269.8 μg / mL and 3A7 anti-I-GEAb mutant 8 protein with a concentration of 377.2 μg / mL were successfully prepared.

[0122] Example 6 Determination of anti-insect activity of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8

[0123] The process of detecting the larvae of diamondback moth: The phage-displayed 3A7 anti-I-GEAb and the phage-displayed Nc-1 (negative control) prepared in Example 3 and the phage-displayed 3A7 anti-I-GEAbmutant8 prepared in Example 4 were taken, and their phage titers were quantified to 1.0×10 9cfu / ml, for later use; 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 protein prepared in Example 5 were also quantified to 500ng / ml with PBS solution, for later use; the negative control was PBS solution, and the positive control was Bt Cry1C toxin of the same concentration. The above-mentioned co-test materials were respectively coated on culture dishes containing solid feed, placed at room temperature to dry, and 20 larvae of Plutella xylostella (conventional non-resistant strain, i.e., sensitive strain) at the 2nd instar larvae stage were selected from each culture dish, and placed in an incubator with a temperature of 28°C±1°C, a relative humidity of 80±5%, and a light cycle (L:D) of 12h:12h. The number of deaths was observed and recorded every 24h, and the statistics were continuously counted for 5 days. If the test larvae continue to survive to the fourth instar and can further emerge, they are judged as alive, otherwise they are judged as dead (Gao et al., "Roles of midgut cadherin from two moths in different Bacillus thuringiensis action mechanisms: correlation among toxin binding, cellular toxicity, and synergism", Journal of agricultural and food chemistry, 2019, Issue 67).

[0124] The bioassay process of cotton bollworm larvae: The phage-displayed 3A7 anti-I-GEAb and phage-displayed Nc-1 (negative control) prepared in Example 3 and the phage-displayed 3A7 anti-I-GEAbmutant8 prepared in Example 4 were taken and their phage titers were fixed to 1.0×10 10cfu / ml, for later use; the 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 proteins prepared in Example 5 were also quantified to 1500ng / ml with PBS buffer for later use; the negative control was PBS solution, and the positive control was Bt Cry1C toxin of the same concentration. The above-mentioned co-test materials were respectively coated on culture dishes containing solid feed, placed at room temperature to dry, and 24 cotton bollworm larvae (conventional non-resistant strain, i.e., sensitive strain) at the 2nd instar larvae stage were selected from each culture dish, and placed in an incubator with a temperature of 28°C±1°C, a relative humidity of 80±5%, and a light cycle (L:D) of 12h:12h for breeding. The number of deaths was observed and recorded every 24h, and the statistics were continuously counted for 5 days. The test larvae were judged to be alive if they continued to survive and their weight exceeded 8 mg / head, otherwise they were judged to be dead (Hao et al., "Synergistic selection of a Helicoverpa armigera cadherin fragmentwith Cry1Ac in different cells and insects", International journal of biological macromolecules, 2020, Issue 164).

[0125] Figure 7These are the anti-insect activity test results of 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 in this example. Among them, (a) is the test result of the lethal activity of antibody 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb against the tested diamondback moth larvae. It can be seen that the average lethality of phage-displayed 3A7 anti-I-GEAb, phage-displayed 3A7anti-I-GEAb mutant 8, purified 3A7 anti-I-GEAb protein, and purified 3A7 anti-I-GEAb mutant 8 protein against diamondback moth were 46.6%, 63.3%, 40%, and 53.3%, respectively, while the PBS solution and phage-displayed NC-1 control groups were 5% and 6.6%, respectively, and the Bt Cry1C toxin positive control group was 100%. This shows that 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 have obvious lethal activity against target pests, although their lethal toxicity to target pests is not as good as that of the original Bt Cry1C toxin, but as a human-derived genetically engineered insecticidal antibody, it has high safety and potential application value. (b) is the lethal activity of antibody 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb against the tested cotton bollworm larvae. The results showed that the average lethality of phage-displayed 3A7anti-I-GEAb, phage-displayed 3A7 anti-I-GEAb mutant 8, purified 3A7 anti-I-GEAb protein, and purified 3A7 anti-I-GEAb mutant 8 protein against cotton bollworm were 31.6%, 43.3%, 26.6%, and 38.3%, respectively, while that of PBS solution and phage-displayed NC-1 control groups were 4.17% and 5.6%, respectively, and that of Bt Cry1C toxin positive control group was 83.3%. This indicates that 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 have obvious lethal activity against target pests, although their lethal toxicity to target pests is not as good as that of the original Bt Cry1C toxin, but as a human-derived genetically engineered insecticidal antibody, it has high safety and potential application value.

[0126] Example 7 Establishment and evaluation of immunoassay method for 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8

[0127] 1. Establishment of IC-ELISA detection method

[0128] IC-ELISA detection method for Bt Cry1C toxin detection was established using 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 protein as coating antigens in conjunction with 7C9-mAb F(ab)2: 3A7 anti-I-GEAb and 3A7anti-I-GEAb mutant 8 proteins were diluted to a mass concentration of 2μg / mL with PBS buffer, and 100μL per well was added to a 96-well ELISA plate and coated overnight at 4℃. The coated plate was removed, washed with 300μL / well PBST buffer, and then MPBS solution was added at 300μL / well, and blocked at 37℃ for 2 hours. The blocking plate was removed and washed with 300 μL / well PBST buffer, and then 50 μL of 7C9-mAb F(ab)2 quantified to 2 μg / mL in PBS solution and 50 μL of competitive inhibitor Bt Cry1C toxin solution diluted in PBS solution with a series of concentration gradients (0.1, 0.5, 1, 5, 10, 20, 50, 100 and 1000 ng / mL) were added to each well. The negative control was PBS, and the cells were incubated at 37°C for 1 hour. The incubation plate was removed and washed with 300 μL / well PBST buffer, and then 100 μL / well of Goat anti-mouse IgG-HRP (diluted 1:5000 in PBS buffer) secondary antibody was added, and the cells were incubated at 37°C for 1 hour. After washing the plate with 300 μL / well PBST buffer, add TMB colorimetric solution at 100 μL / well, develop the color for 15 minutes at 37°C in the dark, and measure the OD of the relevant reaction wells. 450 The corresponding IC-ELISAs competitive inhibition rate standard curve was drawn according to the calculation formula [(PSN)] / (PN)]×100%; where P represents the OD of the positive control 450 Value (test sample is 50 μL 7C9-mAb F(ab)2 solution quantified to 2 μg / mL in PBS solution + 50 μL PBS solution), S represents the OD of each standard 450 Values ​​(test samples are 50 μL of 7C9-mAb F(ab)2 solution quantified to 2 μg / mL in PBS solution and 50 μL of competitive inhibitor solution with a series of concentration gradients diluted in PBS solution), N represents the OD of the negative control 450 Value (test sample is 50 μL PBS solution).

[0129] Figure 8Standard curves of IC-ELISAs for Bt Cry1C toxin detection were established using 3A7 anti-I-GEAb and 3A7anti-I-GEAb mutant 8 corresponding proteins as coating antigens and 7C9-mAb F(ab)2 as detection antibody. The IC-ELISA based on 3A7anti-I-GEAb mutant 8 protein had a detection sensitivity (IC10) of 0.35 ng / ml, a median inhibitory concentration (IC50) of 11.53 ng / ml, and a linear detection range (IC20-IC80) of 1.78-76.49 ng / ml for Bt Cry1C toxin; while the IC-ELISA based on 3A7anti-I-GEAb protein had a detection sensitivity (IC10) of 0.54 ng / ml, a median inhibitory concentration (IC50) of 15.08 ng / ml, and a linear detection range (IC20-IC80) of 2.35-157.65 ng / ml for Bt Cry1C toxin. This indicates that the IC-ELISAs based on 3A7 anti-I-GEAb and 3A7anti-I-GEAb mutant 8 proteins have achieved a high sensitivity level (IC10 lower than ng / ml) for the detection of Bt Cry1C toxin.

[0130] 2. Evaluation of the practicality and practicability of the IC-ELISAs detection method for Bt Cry1C toxin detection based on 3A7 anti-I-GEAb and its mutant 3A7 anti-I-GEAb mutant 8 protein:

[0131] In order to evaluate the practicality and applicability of the IC-ELISAs detection method established above, tap water, non-GMO corn, rice, soybean and farmland soil samples were selected as the objects of Bt Cry1C toxin standard addition recovery test. The tap water sample was taken from the laboratory of the applicant's unit and filtered through a 0.45μm filter membrane for sample addition, while non-GMO rice, wheat, corn (all purchased from Nanjing Suguo Supermarket) and farmland soil (taken from the farmland of the applicant's unit) were air-dried in a 65℃ oven, ground into powder, and then filtered through a 100-mesh sieve before being used for sample addition. According to the linear detection range (2.35-157.65 ng / ml) of the IC-ELISA method for Bt Cry1C toxin established based on the 3A7 anti-I-GEAb protein, the final concentration of the Bt Cry1C toxin standard added to the test sample was selected as 5, 50 and 100 ng / ml or g; according to the linear detection range (1.78-76.49 ng / ml) of the IC-ELISA method for Bt Cry1C toxin established based on the 3A7 anti-I-GEAb mutant 8 protein, the final concentration of the Bt Cry1C toxin standard added to the test sample was selected as 2, 10 and 50 ng / ml or g. The specific operation is that the corresponding concentration of the Bt Cry toxin standard to be tested is added to the tap water sample and then directly determined according to the IC-ELISAs method established in Example 7; and the corresponding concentration of the Bt Cry toxin standard to be tested is added to powder samples such as rice, wheat, corn and farmland soil, and an equal volume of PBS-T-BSA protein extract (PBS buffer containing 0.1% Tween 20 and 0.1% BSA) is added, and then shaken and mixed at room temperature at 25°C for 4 hours, and then centrifuged at 10000g in a centrifuge at 25°C for 10 minutes, the supernatant is aspirated, diluted 10 times with PBS buffer, and then determined according to the corresponding IC-ELISAs method established in Example 7.

[0132] The test results are shown in Table 1 and Table 2 below:

[0133] Table 1. Results of recovery and coefficient of variation of samples spiked with Bt Cry1C toxin using IC-ELISA assay based on 3A7 anti-I-GEAb protein

[0134]

[0135] Table 2 Results of recovery and coefficient of variation of samples spiked with Bt Cry1C toxin using IC-ELISA method based on 3A7 anti-I-GEAb mutant 8 protein

[0136]

[0137] The test results in Tables 1 and 2 show that the IC-ELISAs detection method for Bt Cry1C toxin detection established based on 3A7 anti-I-GEAb protein had recoveries of 81.77%-98.42%, 81.78%-98.20%, 80.17%-97.74%, 85.65%-96.40% and 81.80%-88.01% when Bt Cry1C toxin at different concentration gradients was added to samples such as tap water, rice, wheat, corn and farmland soil, and the corresponding coefficients of variation were 3.49%-8.33%, 1.31%-11.23%, 3.11%-9.12%, 3.11%-9.43% and 2.69%-10.67%, respectively.

[0138] The IC-ELISAs detection method for Bt Cry1C toxin detection established based on 3A7 anti-I-GEAb mutant 8 protein showed recoveries of 86.46%-98.50%, 80.90%-91.50%, 85.20%-94.00%, 83.34%-95.50% and 80.04%-89.20% when Bt Cry1C toxin at different concentration gradients was added to samples such as tap water, rice, wheat, corn and farmland soil, and the corresponding coefficients of variation were 2.96%-9.50%, 4.19%-11.05%, 5.63%-10.86%, 3.23%-11.44% and 5.72%-11.10%, respectively; the IC-ELISAs detection method for Bt Cry1C toxin detection established based on 3A7 anti-I-GEAb and its mutant 3A7anti-I-GEAb mutant 8 protein The IC-ELISAs detection method for Cry1C toxin detection has good accuracy and stability, strong practicality and wide applicability for test samples, and is expected to be used for highly sensitive monitoring of toxin residues in BtCry1C toxin preparations or their genetically modified insect-resistant crops.

Claims

1. A humanized genetically engineered antibody with a structure that simulates the Bt Cry1C toxin and insecticidal function, the amino acid sequence of which is shown in SEQ IN NO.

2.

2. The gene encoding the humanized genetically engineered antibody as claimed in claim 1, wherein the nucleotide sequence thereof is shown in SEQ IN NO.

1.

3. The mutant of the humanized genetically engineered antibody according to claim 1, wherein the amino acid sequence is shown in SEQ IN NO.

4.

4. Use of the humanized genetically engineered antibody as claimed in claim 1 in killing Plutella xylostella or cotton bollworm.

5. Use of the humanized genetically engineered antibody as claimed in claim 1 as a coating antigen in ELISA detection for Bt Cry1C toxin detection.

6. A recombinant expression vector, transgenic cell line or recombinant engineered bacteria containing the gene encoding the humanized genetically engineered antibody as claimed in claim 2.

7. The coding gene of the mutant as claimed in claim 3, whose nucleotide sequence is shown in SEQ IN NO.

3.

8. Use of the mutant according to claim 3 in killing Plutella xylostella or cotton bollworm.

9. Use of the mutant according to claim 3 as a coating antigen in ELISA detection for Bt Cry1C toxin detection.

10. A recombinant expression vector, transgenic cell line or recombinant engineered bacteria containing the mutant encoding gene according to claim 3.

Citation Information

Patent Citations

  • Bovine-derived reshaped antibody with insecticidal activity as well as preparation method and application thereof

    CN105131123A

  • Protein used for broad spectrum detection of Bt (bacillus thuringiensis) Cry toxins as well as coding gene and application thereof

    CN105884892A

  • Polypeptide for simulating general structure and function of Bt Cry toxin as well as coding gene and application of polypeptide

    CN116178512A

  • Improved Human-Derived Insecticidal Bt Cry Toxin Mimetic, And Design Method And Application Thereof

    US20200095336A1